

APR 04 2000

TECH CENTER 1600/2900

- IV. Claims 26-53, 67, 68, 69 and 70, directed to pharmaceutical compositions, a method of raising an immune response and methods of treatment;
- V. Claim 54, directed to anti-sera;
- VI. Claims 55-58, directed to antibodies;
- VII. Claims 59-61, directed to methods of detecting antibodies;
- VIII. Claims 62-64, directed to methods of detecting proteins; and
- IX. Claims 65 and 66, directed to a method of detecting nucleic acids.

In response Applicants elect, with traverse, to prosecute the subject matter of Group II, claims 9-17, 20 and 21, directed to nucleic acids, vectors and host cells. Applicants fully reserve all rights to prosecute the non-elected subject matter in one or more continuation applications.

When this application was filed, an Information Disclosure Statement and modified PTO 1449 Form listing References AA-AH together with a copy of each of References AA-AH were submitted with the application. For convenience, a copy of the Information Disclosure Statement and PTO 1449 Form is submitted herewith. Also submitted herewith is a Supplemental Information Disclosure Statement and modified PTO 1449 Form listing References AI-AJ together with a copy of each of these additional references. It is requested that all the cited references are made of record on the file.

Respectfully submitted,

Date March 29, 2000


Geraldine F. Baldwin 31,232
(Reg. No.)

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090